Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia

Fig. 1

a FAK is activated in the cells of ALL patients. i: Western blot analysis. Cell lysates from freshly isolated ALL (#1–#10) and normal control volunteer (NC1–NC3) cells were prepared and subjected to Western blot analysis. The polyvinylidene fluoride membrane was sequentially probed with anti-FAK. The band intensity was measured via densitometry. ii: Quantitative real-time PCR analysis also showed that the mRNA expression of FAK was increased in ALL patients compared with normal control volunteers. The differences were statistically significant (p < 0.05). b Rapamycin activated AKT and FAK down-regulation inhibited AKT phosphorylation. After treatment with or without 100 nM rapamycin for 10 h, REH-empty vector cells or REH-FAK shRNA cells were subjected to Western blot analysis. AKT was activated by rapamycin, and phospho-AKT was inhibited by the combination treatment with rapamycin and FAK down-regulation

Back to article page